Lantern Pharma Inc. (LTRN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 27, 2025, announces the financial results for Lantern Pharma Inc. for the fiscal year and fourth quarter ended December 31, 2024. The Company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release (Exhibit 99.1) and presentation (Exhibit 99.2) referenced in this report but are not detailed in the 8-K body text itself.
Material Changes
No specific material changes versus prior periods are quantified in this filing. The document serves as a notification that results for the period ended December 31, 2024, have been released via external exhibits.
Guidance, Outlook, and Risks
Management utilized a presentation and conference call to discuss financial and operating results. The filing explicitly states that the information in Item 2.02 and Item 7.01, including the referenced exhibits, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section unless expressly incorporated by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2024.
- Examine Exhibit 99.2 (Presentation) for management's outlook, clinical trial updates, and guidance for 2025.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Confirm any updates to the Company's emerging growth company status and related accounting election.